Discontinued — last reported Q4 '23
W.P. Carey Inc. Total Cost of Revenue decreased by 52.6% to $46.00K in Q4 2023 compared to the prior quarter. Year-over-year, this metric declined by 55.8%, from $104.00K to $46.00K. Over 2 years (FY 2021 to FY 2023), Total Cost of Revenue shows a downward trend with a -69.8% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $968.00K | $1.04M | $985.00K | $927.00K | $1.14M | $344.00K | $104.00K | $101.00K | $124.00K | $97.00K | $46.00K |
| QoQ Change | — | +7.5% | -5.4% | -5.9% | +23.3% | -69.9% | -69.8% | -2.9% | +22.8% | -21.8% | -52.6% |
| YoY Change | — | — | — | — | +18.1% | -67.0% | -89.4% | -89.1% | -89.2% | -71.8% | -55.8% |
| Segment | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|
| Investment Management Segment | $927.00K | $1.14M | $344.00K | $104.00K | $101.00K | $124.00K | $97.00K | $46.00K |
| Total | $927.00K | $1.14M | $344.00K | $104.00K | $101.00K | $124.00K | $97.00K | $46.00K |
Investment Management Segment was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.